Α-Hydroxyetizolam
Α-Hydroxyetizolam is a metabolite of the thienodiazepine etizolam, which is a compound structurally related to benzodiazepines. Α-Hydroxyetizolam is formed in the liver through the process of metabolism and has pharmacological activity similar to its parent compound, etizolam, though typically with a lower potency. The presence of Α-Hydroxyetizolam in biological specimens can be an indicator of etizolam consumption.
Pharmacology
Α-Hydroxyetizolam, like etizolam, acts as an agonist at the GABAA receptor, which is the most prolific inhibitory receptor within the brain. This action enhances the effect of the neurotransmitter GABA (gamma-aminobutyric acid), leading to increased neuronal inhibition and the manifestation of the typical effects of thienodiazepines: muscle relaxation, anxiolysis, sedation, and anticonvulsant effects.
Metabolism
The metabolism of etizolam to Α-Hydroxyetizolam primarily occurs in the liver, mediated by enzymes of the cytochrome P450 family. This metabolic pathway is crucial for the elimination of etizolam from the body and can influence the duration of its pharmacological effects. The detection of Α-Hydroxyetizolam in urine or blood tests can be used to confirm recent use of etizolam, making it significant in the fields of toxicology and forensic science.
Clinical Significance
While Α-Hydroxyetizolam itself is not marketed as a therapeutic agent, its parent compound, etizolam, is used in certain countries for the treatment of anxiety and insomnia. Understanding the metabolism of etizolam, including the formation of Α-Hydroxyetizolam, is important for clinicians to predict drug interactions, side effects, and the duration of action of etizolam.
Legal Status
The legal status of Α-Hydroxyetizolam is generally tied to that of etizolam, which varies by country. In some jurisdictions, etizolam and its metabolites are controlled substances due to their potential for abuse and dependence.
See Also
- Etizolam
- Thienodiazepine
- Benzodiazepine
- [[GABAA receptor]]
- Cytochrome P450
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD